Literature DB >> 10655403

Reliability of the MB/BacT system for testing susceptibility of Mycobacterium tuberculosis complex isolates to antituberculous drugs.

F Brunello1, R Fontana.   

Abstract

The susceptibility of 115 Mycobacterium tuberculosis complex clinical isolates to isoniazid, streptomycin, ethambutol, and rifampin was assessed by the MB/BacT and BACTEC 460TB systems. The correlation between the two tests was 98.3% for isoniazid, 100% for streptomycin and rifampin, and 95.8% for ethambutol. Turnaround times for antimicrobial susceptibility testing ranged from 5 to 11 days (median, 8.5 days) for MB/BacT and from 4 to 8 days (median, 6 days) for BACTEC 460TB.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10655403      PMCID： PMC86230     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  7 in total

1.  Reliability of mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to ethambutol and streptomycin.

Authors:  J S Bergmann; G L Woods
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

2.  The resurgence of tuberculosis: is your laboratory ready?

Authors:  F C Tenover; J T Crawford; R E Huebner; L J Geiter; C R Horsburgh; R C Good
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

3.  Evaluation of the ESP culture system II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculous drugs.

Authors:  J S Bergmann; G L Woods
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

4.  Comparison of the MB/BacT and BACTEC 460 TB systems for recovery of mycobacteria from various clinical specimens.

Authors:  F Brunello; F Favari; R Fontana
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

5.  Evaluation of the MB/BacT system and comparison to the BACTEC 460 system and solid media for isolation of mycobacteria from clinical specimens.

Authors:  P Rohner; B Ninet; C Metral; S Emler; R Auckenthaler
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

6.  Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs.

Authors:  S Rüsch-Gerdes; C Domehl; G Nardi; M R Gismondo; H M Welscher; G E Pfyffer
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

7.  Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens.

Authors:  G D Roberts; N L Goodman; L Heifets; H W Larsh; T H Lindner; J K McClatchy; M R McGinnis; S H Siddiqi; P Wright
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948
  7 in total
  9 in total

1.  Evaluation of a novel kit for use with the BacT/ALERT 3D system for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  Jim Werngren; Lisbeth Klintz; Sven E Hoffner
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 2.  Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems.

Authors:  Claudio Piersimoni; Armando Olivieri; Luca Benacchio; Claudio Scarparo
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

3.  Microscopic-observation drug-susceptibility assay for the diagnosis of TB.

Authors:  David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 91.245

4.  Identification of rifampin-resistant Mycobacterium tuberculosis strains by hybridization, PCR, and ligase detection reaction on oligonucleotide microchips.

Authors:  V Mikhailovich; S Lapa; D Gryadunov; A Sobolev; B Strizhkov; N Chernyh; O Skotnikova; O Irtuganova; A Moroz; V Litvinov; M Vladimirskii; M Perelman; L Chernousova; V Erokhin; A Zasedatelev; A Mirzabekov
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

5.  Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  Pascale Bemer; Frantiska Palicova; Sabine Rüsch-Gerdes; Henri B Drugeon; Gaby E Pfyffer
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

6.  Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method.

Authors:  Claudio Scarparo; Paolo Ricordi; Giuliana Ruggiero; Paola Piccoli
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

7.  Multicenter evaluation of the MB/BACT system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  Pascale Bemer; Thomas Bodmer; Juerg Munzinger; Monique Perrin; Véronique Vincent; Henri Drugeon
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

8.  Usefulness of the GenoType MTBC assay for differentiating species of the Mycobacterium tuberculosis complex in cultures obtained from clinical specimens.

Authors:  Elvira Richter; Michael Weizenegger; Anne-Marie Fahr; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

9.  Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  Montserrat Garrigó; Lina Marcela Aragón; Fernando Alcaide; Sonia Borrell; Eugenia Cardeñosa; Juan José Galán; Julián Gonzalez-Martín; Nuria Martin-Casabona; Carmen Moreno; Margarita Salvado; Pere Coll
Journal:  J Clin Microbiol       Date:  2007-04-18       Impact factor: 5.948
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.